Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q6)Sep 30, 2025 | (FY)Mar 31, 2025 | (Q6)Sep 30, 2024 | (FY)Mar 31, 2024 | (Q6)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q9)Dec 31, 2022 | (Q6)Sep 30, 2022 | (Q1)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 2.59%618.86M | -0.02%1.24B | 5.21%603.21M | 39.64%1.24B | 43.88%573.35M | 42.95%271.66M | 21.06%888.62M | 12.12%725.82M | -0.67%398.49M | 3.18%190.04M |
| Operating income | 2.59%618.86M | -0.02%1.24B | 5.21%603.21M | 39.64%1.24B | 43.88%573.35M | 42.95%271.66M | 21.06%888.62M | 12.12%725.82M | -0.67%398.49M | 3.18%190.04M |
| Cost of sales | 2.10%-582.57M | -7.80%-1.2B | -15.09%-595.06M | -45.04%-1.11B | -56.54%-517.04M | -59.46%-242.53M | -40.30%-767.38M | -26.27%-638.4M | -5.35%-330.28M | -7.13%-152.1M |
| Operating expenses | 2.10%-582.57M | -7.80%-1.2B | -15.09%-595.06M | -45.04%-1.11B | -56.54%-517.04M | -59.46%-242.53M | -40.30%-767.38M | -26.27%-638.4M | -5.35%-330.28M | -7.13%-152.1M |
| Gross profit | 345.35%36.29M | -68.12%40.77M | -85.53%8.15M | 5.48%127.88M | -17.44%56.31M | -23.23%29.13M | -35.19%121.24M | -38.35%87.42M | -22.22%68.2M | -10.12%37.94M |
| Selling expenses | -18.88%-4.34M | 9.32%-7.61M | 16.67%-3.65M | -42.77%-8.39M | -83.09%-4.39M | -109.26%-2.19M | 36.37%-5.88M | 51.63%-3.94M | 53.83%-2.4M | 60.42%-1.05M |
| Administrative expenses | -32.27%-57.64M | -20.36%-95.82M | -4.01%-43.58M | 7.09%-79.61M | -20.66%-41.9M | -31.08%-21.73M | 2.25%-85.68M | 14.24%-58.57M | 20.38%-34.73M | 20.25%-16.57M |
| Research and development expenses | -16.41%-28.82M | -38.28%-60.25M | -41.77%-24.76M | -19.72%-43.57M | -18.42%-17.47M | -40.53%-9.48M | -29.45%-36.39M | -22.17%-25.12M | -12.47%-14.75M | -12.19%-6.75M |
| Impairment and provision | -46.88%298K | 67.19%-80.01M | 4,107.14%561K | 33.50%-243.86M | 98.38%-14K | ---- | -2,823.60%-366.68M | 903.08%4.95M | -191.89%-864K | ---- |
| -Goodwill impairment | ---- | 74.76%-56.74M | ---- | 35.65%-224.84M | ---- | ---- | ---349.39M | ---- | ---- | ---- |
| -Other impairment is provision | -46.88%298K | -22.33%-23.27M | 4,107.14%561K | -9.99%-19.02M | 98.38%-14K | ---- | -37.88%-17.29M | 903.08%4.95M | -191.89%-864K | ---- |
| Operating interest expense | ---- | ---- | ---- | ---- | ---- | -10.83%-5.72M | ---- | -59.31%-18.82M | -56.32%-11.7M | -55.19%-5.16M |
| Special items of operating profit | -44.70%7.84M | -74.91%18.23M | -45.31%14.18M | -55.14%72.64M | -12.45%25.93M | 599.61%19.48M | 213.97%161.92M | 11.17%38.7M | 238.36%29.61M | -41.74%2.79M |
| Operating profit | 5.55%-46.38M | -5.59%-184.69M | -365.78%-49.11M | 17.29%-174.91M | -44.66%18.48M | -15.23%9.49M | -351.65%-211.47M | -63.35%24.63M | 24.82%33.39M | -21.27%11.2M |
| Financing cost | -1.56%-9.48M | 19.97%-19.46M | 12.78%-9.33M | 4.56%-24.31M | ---10.7M | ---- | ---25.47M | ---- | ---- | ---- |
| Share of profits of associates | ---- | -317.45%-2.92M | ---- | -5,725.00%-699K | ---- | ---- | 29.41%-12K | -140.00%-12K | -192.31%-12K | ---11K |
| Earning before tax | 4.41%-55.86M | -3.57%-207.06M | -851.19%-58.44M | 15.63%-199.92M | -76.69%7.78M | -15.15%9.49M | -382.04%-236.96M | -63.36%24.61M | 24.72%33.38M | -21.35%11.19M |
| Tax | -39.60%4.63M | 173.16%3.68M | 305.08%7.66M | -780.65%-5.03M | 125.66%1.89M | 56.53%2.64M | 105.73%739K | 102.01%229K | 109.29%838K | 130.31%1.68M |
| After-tax profit from continuing operations | -0.90%-51.23M | 0.76%-203.38M | -625.08%-50.78M | 13.24%-204.95M | -71.74%9.67M | -5.77%12.13M | -432.09%-236.22M | -55.49%24.84M | 92.85%34.22M | 48.52%12.87M |
| Earning after tax | -0.90%-51.23M | 0.76%-203.38M | -625.08%-50.78M | 13.24%-204.95M | -71.74%9.67M | -5.77%12.13M | -406.95%-236.22M | -54.69%24.84M | 104.65%34.22M | 65.65%12.87M |
| Minority shareholders should account for profits from continuing business | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 14.67%-3.03M | ---- | ---- |
| Minority profit | 131.82%3.17M | 157.45%4.35M | 173.69%1.37M | -28.48%-7.57M | -177.28%-1.86M | 78.27%640K | -73.43%-5.89M | 14.67%-3.03M | 80.76%-669K | 118.20%359K |
| Shareholders should account for profits from continuing business | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -53.05%27.87M | ---- | ---- |
| Profit attributable to shareholders | -4.33%-54.4M | -5.24%-207.73M | -552.43%-52.14M | 14.30%-197.38M | -66.96%11.53M | -8.18%11.49M | -386.66%-230.33M | -52.26%27.87M | 72.72%34.88M | 28.43%12.51M |
| Basic earnings per share | -4.59%-0.0114 | -5.33%-0.0435 | -554.17%-0.0109 | 17.89%-0.0413 | -70.00%0.0024 | -20.00%0.0024 | -361.98%-0.0503 | -55.71%0.0062 | 66.67%0.008 | 30.43%0.003 |
| Diluted earnings per share | -4.59%-0.0114 | -5.33%-0.0435 | -554.17%-0.0109 | 17.89%-0.0413 | -70.00%0.0024 | -20.00%0.0024 | -361.98%-0.0503 | -55.71%0.0062 | 66.67%0.008 | 30.43%0.003 |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS |
| Audit Opinions | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | -- | Unqualified Opinion | -- | -- | -- |
| Auditor | -- | Ernst & Young | -- | Ernst & Young | -- | -- | Ernst & Young | -- | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.